The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. Wilson
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581 · cited 2×
“As in the parental Fab complex, two out of 1050 residues, namely T51 in the VL chain of each Fab fragment, are located in the ``disallowed regions'' (Laskowski et al., 1993) of the Ramachandran plot; 85 % of all residues have their main-chain torsion angles in the ``most favored'' regions.”
BackgroundThe CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,429
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationFolkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Crystallographic R Factor Refinement by Molecular Dynamics
Brünger, A. T., Kuriyan, J., & Karplus, M. (1987) · Science · doi:10.1126/science.235.4787.458 · Cited by 1,956
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
“Currently, anti-VEGF strategies are being explored in clinical trials in AMD patients, using either a recombinant humanized VEGF-specific Fab (rhuFab VEGF”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
BackgroundPapadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Selecting and screening recombinant antibody libraries
Hoogenboom, H. R. (2005) · Nature Biotechnology · doi:10.1038/nbt1126 · Cited by 973
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationIntravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
Boder, E. T., Midelfort, K. S., & Wittrup, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170297297 · Cited by 673
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0601 · Cited by 501
RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
The Role of Vascular Endothelial Growth Factor in Angiogenesis
Ferrara, N., & Gerber, H.-P. (2001) · Acta Haematologica · doi:10.1159/000046610 · Cited by 451
Cytokine detection by antibody-based proximity ligation
Gullberg, M., Gústafsdóttir, S. M., Schallmeiner, E., Jarvius, J., Bjarnegård, M., Betsholtz, C., Landegren, U., & Fredriksson, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400552101 · Cited by 411
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387
Mechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382
“The second approved inhibitor is ranibizumab, a high-affinity humanized monoclonal antibody fragment (Fab) that neutralizes all splice variants of VEGFA with a molecular weight of 48 kDa [60].”
BackgroundVEGF: an update on biological and therapeutic aspects
Ferrara, N. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00153-1 · Cited by 372
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Heier, J. S., Antoszyk, A. N., Pavan, P. R., Leff, S. R., Rosenfeld, P. J., Ciulla, T. A., Dreyer, R. F., Gentile, R. C., Sy, J. P., Hantsbarger, G., et al. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.052 · Cited by 360
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Self-citationPhage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Computational design of antibody-affinity improvement beyond in vivo maturation
Lippow, S. M., Wittrup, K. D., & Tidor, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1336 · Cited by 342
VEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Mechanisms of Angiogenesis · doi:10.1007/3-7643-7311-3_15 · Cited by 312
Fellouse, F. A., Wiesmann, C., & Sidhu, S. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401786101 · Cited by 306
Self-citationBashshur, Z. F., Bazarbachi, A., Schakal, A., Haddad, Z. A., El Haibi, C. P., & Noureddin, B. N. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.037 · Cited by 305
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ohc.2006.05.009 · Cited by 299
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Quantification of protein interactions and solution transport using high-density GMR sensor arrays
Gaster, R. S., Xu, L., Han, S.-J., Wilson, R. J., Hall, D. A., Osterfeld, S. J., Yu, H., & Wang, S. X. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.45 · Cited by 272
SDF-1 is both necessary and sufficient to promote proliferative retinopathy
Butler, J. M., Guthrie, S. M., Koc, M., Afzal, A., Caballero, S., Brooks, H. L., Mames, R. N., Segal, M. S., Grant, M. B., & Scott, E. W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522869 · Cited by 263
Phage display in pharmaceutical biotechnology
Sidhu, S. S. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00152-x · Cited by 262
A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2
Zahnd, C., Wyler, E., Schwenk, J. M., Steiner, D., Lawrence, M. C., McKern, N. M., Pecorari, F., Ward, C. W., Joos, T. O., & Plückthun, A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.028 · Cited by 256
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli
Gaciarz, A., Veijola, J., Uchida, Y., Saaranen, M. J., Wang, C., Hörkkö, S., & Ruddock, L. W. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0419-5 · Cited by 100
“…human IgG 1 (Humira; PDB structures 3WD5, 4NYL [12, 13]; Maa48 [14] and K2 [15]), two humanized IgG 1 (Avas-tin; PDB structures 1BJ1, 1CZ8 [16, 17] and Herceptin; PDB structures 1FVC, 1N8Z, 4HKZ [18–20]), a mouse IgG 1 (3211; An anti-BNP antibody, Veijola, Vuolteenaho and Takkinen,…”
Pantazes, R. J., & Maranas, C. D. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq061 · Cited by 97
“Three systems were selected to test OptCDR’s efficacy: a peptide from the capsid of hepatitis C (PDB: 1N64) (Menez et al., 2003), fluorescein (PDB: 1FLR) (Whitlow et al., 1995) and VEGF (PDB: 1CZ8) (Chen et al., 1999).”
BackgroundMethodInfluentialDillon, M., Yin, Y., Zhou, J., McCarty, L., Ellerman, D., Slaga, D., Junttila, T. T., Han, G., Sandoval, W., Ovacik, M. A., et al. (2017) · mAbs · doi:10.1080/19420862.2016.1267089 · Cited by 75
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Park, J. A., Espinosa-Cotton, M., Guo, H.-F., Monette, S., & Cheung, N.-K. V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006680 · Cited by 46
Pongsachareonnont, P., Ying Kit Mak, M., Hurst, C., & Lam, W.-C. (2018) · Clinical Ophthalmology · doi:10.2147/opth.s171636 · Cited by 34
“…is an affinity-matured antigen-binding fragment (Fab) with high affinity for VEGF-A and neutralizes all human VEGF-A isoforms, except for PLGF. 33,34 Our finding of an increase in the PLGF level in patients who did not respond to ranibizumab mono-therapy is consistent with the evidence of…”
Metadata
- Authors
- Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 1999-11
- Volume
- 293
- Issue
- 4
- Pages
- 865-881
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W1972242350
- Cited by
- 448
- References
- 47
- Type
- book review
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.